Related Experiment Video

Updated: Aug 7, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma

L Mas1, J Cros2, M Svrcek3

  • 1Department of Hepato-Gastroenterology and Digestive Oncology, Pitié Salpêtrière Hospital, APHP, 47-83 Boulevard de l'Hôpital, Paris 75013, France; Sorbonne University, UPMC University, 15-21 Rue de l'École de Médecine, Paris 75006, France.

Clinics and Research in Hepatology and Gastroenterology
|March 6, 2023
PubMed
Abstract

Insights

Trop-2 is highly expressed in pancreatic ductal adenocarcinoma (PDAC) tumor cells, showing consistent levels between primary and metastatic sites. This ubiquitous marker presents a promising therapeutic target for PDAC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Trop-2 is overexpressed in various cancer types, including pancreatic ductal adenocarcinoma (PDAC).
  • Trop-2 has emerged as a significant therapeutic target in oncology.
  • Understanding Trop-2 expression in PDAC is crucial for targeted therapy development.

Purpose of the Study:

  • To evaluate Trop-2 expression at transcriptomic and protein levels in PDAC.
  • To correlate Trop-2 expression with tumor characteristics and patient outcomes.
  • To assess Trop-2 as a potential therapeutic target in PDAC.

Main Methods:

  • Analysis of transcriptomic profiles from FFPE tissue samples of PDAC patients.
  • Evaluation of protein expression using immunohistochemistry (IHC) on tissue micro-arrays.
  • Inclusion of 495 patients from 5 academic hospitals in France and Belgium (1996-2012).

Main Results:

  • Trop-2 mRNA expression was associated with tumor cellularity but not survival or pathological features.
  • High Trop-2 mRNA expression was consistent across all patient subgroups and between primary and metastatic lesions.
  • Immunohistochemistry revealed high or medium Trop-2 expression in 98% of assessed PDAC tumors, correlating significantly with mRNA levels but not survival.

Conclusions:

  • Trop-2 overexpression is a ubiquitous characteristic of PDAC tumor cells.
  • Trop-2 represents a promising and validated therapeutic target for PDAC.
  • Further evaluation of Trop-2-targeted therapies in PDAC patients is warranted.
Keywords:
Antibody-drug conjugatePDACPancreatic ductal adenocarcinomaTrop-2

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.3K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K